Intravenous Lignocaine Infusion for Intractable Pain in Ewing's Sarcoma

Area of Science:

• Palliative Care
• Oncology
• Pain Management

Background:

• Ewing's sarcoma is a rare bone cancer that can cause severe, intractable pain.
• Palliative care aims to manage pain and improve quality of life for patients with advanced cancer.
• Opioid medications are standard for cancer pain but can have dose-limiting side effects and tolerance issues.

Observation:

• A 23-year-old female with advanced Ewing's sarcoma experienced severe arm pain unresponsive to conventional analgesics, including opioids.
• The patient was unable to tolerate increased opioid doses due to side effects.
• Her pain significantly impacted her quality of life, leading to distress.

Findings:

• An intravenous lignocaine infusion (2 mg/kg/hr for 3 days) provided significant pain relief.
• Following the lignocaine infusion, the patient's pain was managed with her original medication regimen.
• The patient's distress was alleviated, and her quality of life improved.

Implications:

• Intravenous lignocaine infusion is a potentially safe and effective adjunct for managing intractable cancer pain in palliative care.
• This treatment may be particularly useful for patients with opioid tolerance or side effects.
• Further research into lignocaine's role in refractory cancer pain management is warranted.